GNRO Stock Overview
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases.
+ 2 more risks
Price History & Performance
|Historical stock prices|
|Current Share Price||€2.19|
|52 Week High||€4.24|
|52 Week Low||€2.07|
|1 Month Change||-5.20%|
|3 Month Change||-28.66%|
|1 Year Change||-46.06%|
|3 Year Change||-37.43%|
|5 Year Change||-80.92%|
|Change since IPO||-82.09%|
Recent News & Updates
|GNRO||FR Biotechs||FR Market|
Return vs Industry: GNRO underperformed the French Biotechs industry which returned -41% over the past year.
Return vs Market: GNRO underperformed the French Market which returned -6.7% over the past year.
|GNRO Average Weekly Movement||6.9%|
|Biotechs Industry Average Movement||6.6%|
|Market Average Movement||5.0%|
|10% most volatile stocks in FR Market||9.0%|
|10% least volatile stocks in FR Market||2.9%|
Stable Share Price: GNRO is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: GNRO's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients.
GeNeuro Fundamentals Summary
|GNRO fundamental statistics|
Is GNRO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GNRO income statement (TTM)|
|Cost of Revenue||€0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.27|
|Net Profit Margin||0.00%|
How did GNRO perform over the long term?See historical performance and comparison
Is GNRO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GNRO?
Other financial metrics that can be useful for relative valuation.
|What is GNRO's n/a Ratio?|
Price to Book Ratio vs Peers
How does GNRO's PB Ratio compare to its peers?
|GNRO PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
ALACT Acticor Biotech SAS
ABVX ABIVAX Société Anonyme
Price-To-Book vs Peers: GNRO is expensive based on its Price-To-Book Ratio (23.3x) compared to the peer average (4.6x).
Price to Earnings Ratio vs Industry
How does GNRO's PE Ratio compare vs other companies in the FR Biotechs Industry?
Price-To-Book vs Industry: GNRO is expensive based on its Price-To-Book Ratio (23.3x) compared to the French Biotechs industry average (2.5x)
Price to Book Ratio vs Fair Ratio
What is GNRO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||23.3x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate GNRO's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of GNRO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GNRO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GNRO's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is GeNeuro forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GNRO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GNRO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GNRO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GNRO is forecast to have no revenue next year.
High Growth Revenue: GNRO is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GNRO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has GeNeuro performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GNRO is currently unprofitable.
Growing Profit Margin: GNRO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GNRO is unprofitable, but has reduced losses over the past 5 years at a rate of 6.9% per year.
Accelerating Growth: Unable to compare GNRO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GNRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).
Return on Equity
High ROE: GNRO has a negative Return on Equity (-290.92%), as it is currently unprofitable.
Discover strong past performing companies
How is GeNeuro's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: GNRO's short term assets (€4.6M) exceed its short term liabilities (€2.6M).
Long Term Liabilities: GNRO's short term assets (€4.6M) exceed its long term liabilities (€2.5M).
Debt to Equity History and Analysis
Debt Level: GNRO has more cash than its total debt.
Reducing Debt: GNRO's debt to equity ratio has increased from 1% to 60.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if GNRO has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if GNRO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is GeNeuro current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GNRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GNRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GNRO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GNRO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GNRO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jesus Martin-Garcia (60 yo)
Mr. Jesús Martin-Garcia is the Founding Partner, General Partner, and Director of Eclosion SA. He serves at GeNeuro SA as the Chairman of the Board since February 06, 2006 and Chief Executive Officer since...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Jesus's total compensation is reasonable compared to companies of similar size in the French market.
Compensation vs Earnings: Jesus's compensation has been consistent with company performance over the past year.
Experienced Management: GNRO's management team is considered experienced (4.4 years average tenure).
Experienced Board: GNRO's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.1%.
GeNeuro SA's employee growth, exchange listings and data sources
- Name: GeNeuro SA
- Ticker: GNRO
- Exchange: ENXTPA
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €54.493m
- Shares outstanding: 24.88m
- Website: https://www.geneuro.com
Number of Employees
- GeNeuro SA
- 3 chemin du PrE-Fleuri
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/08 00:00|
|End of Day Share Price||2022/08/08 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.